Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
26 Results for "
lymphoid leukemia
" in MedChemExpress (MCE) Product Catalog:
Products (26)
26 Results for "lymphoid leukemia" in MCE Product Catalog:
9
9 Publications Verification
SD-36 is a potent STAT3 PROTAC degrader with a Kd of 44.4 nM and a Ki of 11 nM. SD-36 recruits the cereblon/culin 4A E3 ligase complex to mediate ubiquitination and proteasomal degradation of STAT3, inducing G1 phase cell cycle arrest and apoptosis. SD-36 is useful for research on acute myeloid leukemia, anaplastic large cell lymphoma, and hematopoietic and lymphoid malignancies .
3
2
Research Areas:
Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
Mocravimod (KRP-203 free base) is a sphingosine-1-phosphate receptor (S1PR) modulator that blocks the signal required by T cells to egress from lymph nodes and other lymphoid organs. Mocravimod preferentially binds to S1PR1 over S1PR2 and S1PR3 in cardiomyocytes. Mocravimod significantly lowered the concentration of reactive oxygen species (ROS), prevented mitochondrial permeability transition pore opening, boosted mitochondrial membrane potential (MMP), and increased phosphorylation of AKT, EKR, GSK-3β, JAK2, and STAT3. Mocravimod retains T cell effector function. Mocravimod can be used for the study of acute myelogenous leukemia, diabetes and Myocardial Ischemia-Reperfusion Injury (MIRI) .
2
Research Areas:
Mocravimod (hydrochloride) is an orally active sphingosine-1-phosphate receptor (S1PR) modulator that blocks the signal required by T cells to egress from lymph nodes and other lymphoid organs. Mocravimod (hydrochloride) preferentially binds to S1PR1 over S1PR2 and S1PR3 in cardiomyocytes. Mocravimod (hydrochloride) significantly lowered the concentration of reactive oxygen species (ROS), prevented mitochondrial permeability transition pore opening, boosted mitochondrial membrane potential (MMP), and increased phosphorylation of AKT, EKR, GSK-3β, JAK2, and STAT3. Mocravimod (hydrochloride) retains T cell effector function. Mocravimod (hydrochloride) can be used for the study of acute myelogenous leukemia, diabetes and Myocardial Ischemia-Reperfusion Injury (MIRI) .
Cat. No.: HY-P99650
CAS No.: 2367001-70-3
Synonyms: WT1
Target:
Research Areas:
WDR5-0102 is an inhibitor of WDR5. WDR5-0102 specifically targets the WIN site of WDR5, disrupts the WDR5-MLL1 interaction, and reduces the histone methyltransferase activity of MLL1. WDR5-0102 exerts dose-dependent toxicity on MDSC-like cells and reduces their osteopontin levels, while showing extremely low cytotoxicity to pancreatic cancer cells. WDR5-0102 can be used in the research of related diseases such as acute myeloid leukemia, lymphoid leukemia, biphenotypic leukemia and pancreatic cancer .
Target:
Terminal deoxyribonucleotidyltransferase (TdT) catalyses the condensation of deoxyribonucleotide triphosphates onto the 3' hydroxyl ends of DNA strands and adds N-regions to gene segment junctions during V(D)J recombination. Terminal deoxyribonucleotidyltransferase is expressed in immature, pre-B, pre-T lymphoid cells, and acute lymphoblastic leukemia/lymphoma cells .
Cat. No.: HY-153953
CAS No.: 2760536-88-5
Target:
Research Areas:
Bcl-2-IN-11 (compound 6) is a potent and selective Bcl-2 activity inhibitor, with an IC50 of 0.9 nM. Bcl-2-IN-11 shows weak inhibition of Bcl-xl (IC50 > 1000 nM). Bcl-2-IN-11 can be used for the research of a variety of cancers caused by abnormal overexpression of Bcl-2 family proteins: especially malignant hematologic diseases of acute lymphoid leukemia, etc. Bcl-2-IN-11 can also avoid toxic side effects caused by Bcl-xl inhibition, such as thrombocytopenia .
Cat. No.: HY-122518
CAS No.: 51989-25-4
Target:
Research Areas:
8-Deazafolic acid is an antimicrobial drug for the folate-dependent bacteria, Streptococcus faecium (ATCC 8043) and Lactobacillus casei (ATCC 74691). 8-Deazafolic acid has activity against lymphoid leukemia L1210 in mice .
Cat. No.: HY-128744R
CAS No.: 4408-78-0
Cat. No.: HY-P991425
Target:
Research Areas:
AT-1413 is a monoclonal antibody targeting CD43s that recognizes a unique sialylated CD43 epitope spanning amino acid residues 133-165. AT1413 induces antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) in AML cells, with EC50 values of 1.1 nM and 12.4 nM, respectively. AT-1413 binds to a variety of cancer cells, shows weak binding to non-malignant myeloid cells and endothelial cells, and does not bind to healthy lymphoid cells or normal non-hematopoietic cells. AT1413 clears CD43s-expressing leukemic blasts in vivo without affecting non-malignant myeloid cells. AT-1413 can be used in research related to acute myeloid leukemia, myelodysplastic syndrome, melanoma, and breast cancer .
Cat. No.: HY-W1057999
CAS No.: 104149-14-6
Target:
Research Areas:
Bromofosfamide is a prodrug-type alkylating agent and also an analog of Ifosfamide (HY-17419). Bromofosfamide exhibits potent in vivo anti-tumor activity against lymphoid leukemia and can be used for the research of lymphoid leukemia .
Cat. No.: HY-P701135
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: PICALM; CLTH; Phosphatidylinositol Binding Clathrin Assembly Protein; Clathrin Assembly lymphoid Myeloid leukemia Protein; CALM; Alternative Protein PICALM; Phosphatidylinositol-Binding Clathrin Assembly Protein; LAP
Species:
Human
Source:
HEK293
Cat. No.: HY-P84475
Synonyms: ALL1; CXXC7; HRX; HTRX; MLL; MLL1; TRX1; KMT2A; Histone-lysine N-methyltransferase 2A; Lysine N-methyltransferase 2A; ALL-1; CXXC-type zinc finger protein 7; Cysteine methyltransferase KMT2A; Myeloid/lymphoid or mixed-lineage leukemia; Myeloid/lymphoid or mixed-lineage leukemia protein 1; Trithorax-like protein; Zinc finger protein HRX
Cat. No.: HY-P85279
Synonyms: ALL1; CXXC7; HRX; HTRX; MLL; MLL1; TRX1; KMT2A; Histone-lysine N-methyltransferase 2A; Lysine N-methyltransferase 2A; ALL-1; CXXC-type zinc finger protein 7; Cysteine methyltransferase KMT2A; Myeloid/lymphoid or mixed-lineage leukemia; Myeloid/lymphoid or mixed-lineage leukemia protein 1; Trithorax-like protein; Zinc finger protein HRX
Cat. No.: HY-P84475A
Synonyms: ALL1; CXXC7; HRX; HTRX; MLL; MLL1; TRX1; KMT2A; Histone-lysine N-methyltransferase 2A; Lysine N-methyltransferase 2A; ALL-1; CXXC-type zinc finger protein 7; Cysteine methyltransferase KMT2A; Myeloid/lymphoid or mixed-lineage leukemia; Myeloid/lymphoid or mixed-lineage leukemia protein 1; Trithorax-like protein; Zinc finger protein HRX
Cat. No.: HY-P85279A
Synonyms: ALL1; CXXC7; HRX; HTRX; MLL; MLL1; TRX1; KMT2A; Histone-lysine N-methyltransferase 2A; Lysine N-methyltransferase 2A; ALL-1; CXXC-type zinc finger protein 7; Cysteine methyltransferase KMT2A; Myeloid/lymphoid or mixed-lineage leukemia; Myeloid/lymphoid or mixed-lineage leukemia protein 1; Trithorax-like protein; Zinc finger protein HRX
Cat. No.: HY-P703634
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: KMT2C; Homologous To ALR Protein; Prev. MLL3; Myeloid/lymphoid Or Mixed-Lineage leukemia 3; Histone-Lysine N-Methyltransferase 2C; [Histone H3]-Lysine(4) N-Methyltransferase; HALR; Histone-Lysine N-Methyltransferase MLL3; KIAA1506; Lysine N-Methyltransfer
Species:
Human
Source:
E. coli
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
